PPDTM CorEvitasTM Vitiligo Drug Safety and Effectiveness Registry for Adults & Adolescents

NCT07659418 | Enrolling By Invitation

• 1 other identifier: CorEvitas-VIT-520
• Study Type: observational
• Target: 2,500
• Locations: 1 country
• Sites: 1

Brief Summary

The design is a prospective, observational (non-interventional) registry for adolescent and adult subjects with NSV under the care of a dermatology provider.

Conditions

Vitiligo

Outcome Measures

Primary Outcomes (1)

• Vitiligo Epidemiology and presentation

  The major clinical outcome include an assessment of the epidemiology of Vitiligo. This will be determined using PROs and ClinROs which will be included as part of the case report forms.

  Every 6 months for 10 years]

Eligibility Criteria

• Age: 12 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Subjects enrolled in this registry will be treated according to routine clinical care; the assignment of subjects to any treatment will not be determined in advance by the protocol and will be clearly separated from the decision to include subjects in the registry

You may qualify if:

• Individuals are eligible for enrollment if they meet all of the following criteria:
• Have a dermatologist- or qualified dermatology practitioner-confirmed diagnosis of nonsegmental vitiligo (NSV).
• Is at least 12 years of age or older at the time of enrollment.
• Is willing and able to provide informed consent or assent, with parent/legal guardian consent as applicable.
• Adult participants are willing and able to provide required personal information
• Full legal name, sex, date of birth, and home ZIP/postal code
• Meet the criteria for one of the following enrollment cohorts at the time of enrollment:
• Cohort 1: Eligible Medication Initiators - Individuals initiating a prescribed eligible NSV medication at the time of enrollment.
• Cohort 2: Not Initiating Eligible Medication - Individuals not currently receiving NSV medication at the time of enrollment, Individuals receiving eligible NSV medication prior to enrollment.

You may not qualify if:

• An individual who meets any of the following criteria will be excluded from participation in the registry:
• \- Is participating or planning to participate in a blinded clinical trial for a vitiligo therapy.

Sponsors & Collaborators

• CorEvitas: lead

Study Sites (1)

CorEvitas, LLC

Waltham, Massachusetts, 02451, United States

Location

MeSH Terms

Conditions

Vitiligo

Condition Hierarchy (Ancestors)

Hypopigmentation; Pigmentation Disorders; Skin Diseases; Skin and Connective Tissue Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: NETWORK
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 11, 2026
• First Posted: June 22, 2026
• Study Start: June 1, 2026
• Primary Completion (Estimated): December 31, 2099
• Study Completion (Estimated): December 31, 2099
• Last Updated: June 22, 2026

Record last verified: 2026-06

Locations

US (1)